- letzte 200 News
- Archiv
| Zeit | Aktuelle Nachrichten | Rating | Leser | ||
|---|---|---|---|---|---|
| 14.10. | Altron - Strong earnings growth in H125 | 275 | Altron has provided an H125 trading update pointing to a more than doubling of headline EPS from continuing operations and an even larger increase in reported EPS. Having restated comparatives to reflect... ► Artikel lesen | ||
| 14.10. | JPMorgan European Discovery Trust - European small caps: On the verge of a rebound? | 356 | JPMorgan European Discovery Trust (JEDT) invests in European small-cap companies (excluding UK). European small caps have outperformed most other markets over the long term, although they underperformed... ► Artikel lesen | ||
| 14.10. | Argent Biopharma - Valuation report | 286 | We value Argent at an un-risked net present value (NPV) of US$1.1bn. Adjusting for the company's specified probabilities of success (PoS) for its three clinical programmes gives a risk-adjusted NPV... ► Artikel lesen | ||
| 14.10. | 1Spatial - Contract momentum underpins growth prospects | 181 | 1Spatial's H1 results showed a continued improvement in the quality of revenues, while recent deal flow provides good support for our expectation of faster growth and margin expansion from H2. Most... ► Artikel lesen | ||
| 11.10. | Basilea Pharmaceutica - Milestone march continues for Cresemba | 337 | Basilea Pharmaceutica has reported another US$1.25m milestone payment from its partner Pfizer in Asia-Pacific and China, triggered by Cresemba sales in this region crossing a pre-defined threshold.... ► Artikel lesen | ||
| 11.10. | Sareum Holdings - New funding extends runway to Phase II | 283 | Sareum Holdings has announced the completion of a £2.4m private placement and receipt of another A$1.9m (c £1m) in R&D tax credits from Australian authorities, related to the Phase I clinical trial... ► Artikel lesen | ||
| 11.10. | Ocean Wilsons Holdings Limited - Confirmation of interest in Wilson Sons holding | 235 | Ocean Wilsons Holdings' (OCN's) H124 results showed good growth, reflecting a strong performance from Wilson Sons and a positive performance from the investment portfolio (OWIL). While the strategic... ► Artikel lesen | ||
| 11.10. | IP Group - Record exit underpinning the NAV | 227 | IP Group's realisation activity has picked up notably in the months leading up to the company's interim results publication in September, encouraging the company to increase the current buyback programme... ► Artikel lesen | ||
| 10.10. | Centaur Media - Tough trading backdrop persists in H2 | 201 | Centaur's management has reframed its outlook for the remainder of FY24 to reflect the continuing difficult trading environment for XEIM, where its clients (predominantly major global brand owners)... ► Artikel lesen | ||
| 10.10. | Baillie Gifford US Growth Trust - Seeking tomorrow's mega caps | 210 | The managers of Baillie Gifford US Growth Trust (USA), Gary Robinson and Kirsty Gibson, invest in exceptional US businesses with the potential to grow substantially faster than the market and deliver... ► Artikel lesen | ||
| 10.10. | MoneyHero - Investing for the long term | 198 | MoneyHero's Q224 results reflect management's strategy of growing market share in its core geographies, as it invests in advertising, customer rewards and its platforms. Approved application conversion... ► Artikel lesen | ||
| 09.10. | UIL - Announcement of 2028 privatisation plans | 126 | On 8 October 2024, UIL Limited (UIL) announced plans to take the company private after the redemption of the 2028 zero dividend preference (ZDP) shares. UIL's board has decided that despite holding... ► Artikel lesen | ||
| 09.10. | OSE Immunotherapeutics - Riding the H124 tailwinds | 266 | OSE Immunotherapeutics has reported its results for H124, a standout period for the company's development pipeline, with the momentum carrying into H224. The first half of the year rewarded the company... ► Artikel lesen | ||
| 09.10. | 1Spatial - Federal-level win in the US | 191 | 1Spatial's momentum in the US has continued, with the company securing a $1.4m deal with the United States Forest Service (USFS). This is a new Federal government-level deal for the business, building... ► Artikel lesen | ||
| 08.10. | IRLAB Therapeutics - IRL757 progress prompts $2.5m milestone payment | 236 | IRLAB Therapeutics has announced that it will receive a $2.5m milestone payment from the McQuade Center for Strategic Research and Development (MSRD), prompted by the dosing of the first participant... ► Artikel lesen | ||
| 08.10. | CI Games - Strategic roadmap to 2028 | 272 | CI Games outlined its updated strategy to 2028 at its H124 results. The strategy focuses on greater efficiencies to produce higher-quality games, while growing its audience base, and includes three... ► Artikel lesen | ||
| 07.10. | Actinogen Medical - Funding in place to complete XanaMIA Phase IIb | 200 | Actinogen Medical announced a capital increase of up to A$11.1m on 18 September, consisting of the successful completion of an A$8.1m (gross) share placement to existing shareholders and new institutional... ► Artikel lesen | ||
| 07.10. | Games Workshop Group - Sigmar the fourth | 340 | Games Workshop Group (GAW) is the global leader for tabletop miniature gaming, which has enjoyed impressive growth, with core revenue and total operating profit CAGRs of 17% and 19%, respectively, since... ► Artikel lesen | ||
| 04.10. | Card Factory - Confident on FY25 outlook | 296 | Card Factory's H125 revenue growth demonstrated it is delivering well against its multi-year growth strategy. While profitability was negatively affected by the (mostly) known inflation in operating... ► Artikel lesen | ||
| 04.10. | Immix Biopharma - US CAR-T trial progresses to dose expansion | 297 | Immix Biopharma's US-based NEXICART-2 trial continues to make steady progress through the clinic, with the company reporting that the trial has advanced to the dose expansion level of 450m cells, after... ► Artikel lesen | ||
| 03.10. | Helios Underwriting - Strategic shift from growth to consolidation | 301 | Helios Underwriting (Helios) delivered EPS growth of 35% to 7.7p in H124 and reported a net asset value (NAV) of 191p/share. While its combined ratio of 91.6% deteriorated from 88% in H123 and 85% in... ► Artikel lesen | ||
| 03.10. | Henderson Opportunities Trust - Taking AIM at the opportunity | 236 | With a focus on long-term growth, Henderson Opportunities Trust (HOT) seeks investment opportunities across the breadth of the UK market. This includes a strong bias towards smaller and earlier-stage... ► Artikel lesen | ||
| 03.10. | IRLAB Therapeutics - IRL757 starts strong in Phase I | 191 | IRLAB Therapeutics has announced an encouraging update for the ongoing Phase I trial for IRL757, which is being developed as a potential treatment for apathy. The single ascending dose (SAD) portion... ► Artikel lesen | ||
| 03.10. | Tetragon Financial Group - Tetragon maintains its investing pace | 239 | Tetragon Financial Group (Tetragon) reported a 1.3% return on equity (RoE) in H124, with its net asset value (NAV) per share increasing by 1.9% in US dollar total return (TR) terms, and further 3.8%... ► Artikel lesen | ||
| 02.10. | Cereno Scientific - CS1 shines in Phase IIa PAH trial | 230 | Cereno Scientific has reported positive top-line results for the Phase IIa CS1-003 trial, which evaluated the HDAC inhibitor CS1 in pulmonary arterial hypertension (PAH). The primary endpoint of safety... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
